The British Yeast Group Meeting 2016 was held at Swansea University and hosted by the Centre
for Cytochrome P450 Biodiversity. The conference attracted an international mix of attendees with talks ranging from fundamental eukaryotic biology to yeast as a model for human disease.
During the event, Moleculomics CEO Dr Jonathan Mullins unveiled Yeast3DProteome: A comparative structural bioinformatics platform for yeasts. The platform developed for academic use is a collaboration between Moleculomics and the Genome and Structural Bioinformatics group at Swansea University and provides a platform facilitating comparison between two yeast species of great scientific and commercial importance; Saccharomyces cerevisiae and Saccharomyces pombe. These yeasts are frequently used for commercial applications such as brewing and baking and are also popular model organisms for a range of molecular and cell biology studies. Dr Mullins commented “the application of this platform to two important members of the yeast family is a significant milestone in the development of our Human3DProteome tool, planned for early 2017”. Human3DProteome will, for the first time, enable the high throughput screening of candidate small molecule compound(s) against every protein in the human body – a library of 30,000+ potential drug targets. More information regarding this product will become available in the coming months. In the meantime, the Yeast3DProteome is a free resource available here; http://proteinmodelling-server.swan.ac.uk/yeast3Dproteome/
About Moleculomics
As a vehicle for the advancement of alternative technologies for small molecule discovery and purposing, Moleculomics, a UK university spin-out company formed in 2012 has developed powerful in silico protein structural modelling and ligand docking platforms, at proteome-scale for simulating real-life conditions and molecular interactions at whole system level. R&D is built on a track record of structural modelling research featured in >50 journal publications. Over the past four years Moleculomics have been delivering commercial R&D programs including both Hit-to-Lead and toxicity screening work in prestigious projects with UK Ministry of Defence (MoD), Unilever, Dow and NC3Rs resulting in a range of technologies described as “world leading”. For more information, please visit www.moleculomics.com
